TABLE 1.

Phenotypic and genotypic characteristics of T. indotineae strains used in this study

T. indotineae strains a	TBF MIC80 (μg/mL) d	ITC MIC80 (μg/mL) d	VRC MIC80 (μg/mL) d	Fold expression of TinCYP51B (mean ± SD) b	Number of TinCYP51B alleles (mean ± SD) c	Strain type
TIMM20114	0.125	0.06	0.015	1	1	Azole susceptible
(UKJ1676/17; IFM 67092)
TIMM20115	8	0.06	0.03	1.0 ± 0.4	0.9 ± 0.2	Azole susceptible
(UKJ1700/17II; IFM67093)
TIMM20116	0.125	0.5	0.5	34.0 ± 5.3	5.3 ± 0.8	Type I
(UKJ1708/17; IFM 67094)
TIMM20118	8	0.5	1	29.8 ± 4.4	5.5 ± 0.6	Type I
(UKJ1687/17; IFM 67096)
TIMM20119	8	1	1	89.9 ± 26.2	8.9 ± 0.6	Type I
(200123/18; IFM 67097)
TIMM20117	0.125	0.5	0.5	9.9 ± 3.8	10.8 ± 0.6	Type II
(200087/18; IFM 67095)
TIMM20120	0.125	0.25	1	12.5 ± 5.0	10.0 ± 1.2	Type II
(250082/18)
TIMM20121	8	0.5	1	23.4 ± 11.6	14.0 ± 0.05	Type II
(250084/18)
TIMM20122	8	0.5	0.5	22.0 ± 8.0	7.9 ± 0.3	Type II
(250108/18)
TIMM20123	0.125	1	0.5	6.2 ± 2.5	6.4 ± 0.4	Type II
(600097/19)

^a All strains were from a previously published resistance study in India, with the numbering in bold (10). They were then preserved in the culture collection of Teikyo University Institute of Medical Mycology (TIMM), some of which were also preserved in the culture collection of Medical Mycology Research Center, Chiba University (IFM), through the National Bio-Resource Project, Japan (http://www.nbrp.jp/).

^b The results represent expression levels from three independent real-time PCR experiments. The expression levels of TinCYP51B genes were indicated as relative fold changes compared to the ΔCt mean of the data from TIMM20114 (control with a single copy of TinCYP51B). SD, standard deviation.

^c Data were obtained from three independent qPCR experiments using genomic DNA as a target. The TinCYP51B gene copy number of each strain was indicated as relative fold change compared to the ΔCt mean of the data from TIMM20114.

^d TBF, terbinafine; ITC, itraconazole; VRC, voriconazole.